Earning Analysis
Welcome to our in-depth analysis of Verastem Inc(VSTM) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Verastem Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-04 | Pre-Market | -0.51 | -1.35 | -164.71 | 5.76M | 11.24M | +95.18 | -20.10 | -18.48 |
| FY2025Q2 | 2025-08-07 | After Hours | -0.59 | -0.39 | +33.90 | 1.12M | 2.14M | +91.49 | +19.93 | +42.70 |
| FY2024Q4 | 2025-03-20 | - | - | - | - | 150.00K | - | - | -2.29 | -8.31 |
| FY2024Q3 | 2024-11-06 | - | -0.71 | -0.60 | +15.49 | 44.44K | - | - | +3.48 | +17.65 |
| FY2024Q1 | 2024-05-09 | - | -1.16 | -1.26 | -8.62 | - | - | - | +4.56 | +15.09 |
| FY2023Q4 | 2024-03-14 | - | -0.82 | -1.02 | -24.39 | - | - | - | -2.23 | +9.78 |
| FY2023Q3 | 2023-11-08 | - | -0.92 | -0.75 | +18.48 | 28.57K | - | - | +0.14 | -11.76 |
| FY2023Q2 | 2023-08-08 | - | -1.13 | -1.37 | -21.24 | 16.67K | - | - | -1.86 | -6.75 |
| - | 2023-05-09 | - | -0.09 | -0.08 | +11.11 | - | - | - | +2.38 | - |
| - | 2022-11-03 | - | -0.12 | -0.09 | +25.00 | - | - | - | +2.56 | -2.56 |
VSTM Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Verastem Inc reported performance for FY2025Q3, announced on 2025-11-04. The company achieved an EPS of -1.35, compared to analyst estimates of -0.51 by -164.71% . Revenue for the quarter reached 11.24M compared to expectations of 5.76M by 95.18% .
The stock price reacted with a -20.10% one-day change and a -18.48% five-day change following the earnings release. These movements reflect market reaction in Verastem Inc growth trajectory and strategic initiatives.
VSTM Earnings Forecast
Looking ahead, Verastem Inc(VSTM) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 16.84M and an EPS of -0.55.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 66.76%, while EPS estimates have been Revise Upward by 20.63%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 51.65% . These revisions correlate with a -1.58% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Verastem Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between VSTM's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+66.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+20.63%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+51.65%
In Past 3 Month
Stock Price
Go Down
-1.58%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:30.76M
--
EPS Estimate-Annual FY 2025:-3.15
—
Stock Price10.60
VSTM Revenue and EPS Performance: A Historical Perspective
Verastem Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-04,Pre-Market):
EPS: -1.35 (Actual) vs.-0.51 (Estimate) (-164.71%)
Revenue: 11.24M (Actual) vs. 5.76M (Estimate) (95.18%)
Price Reaction: -20.10%(1-Day), -18.48%(5-Day)
FY2025Q2 (2025-08-07,After Hours):
EPS: -0.39 (Actual) vs.-0.59 (Estimate) (33.90%)
Revenue: 2.14M (Actual) vs. 1.12M (Estimate) (91.49%)
Price Reaction: 19.93%(1-Day), 42.70%(5-Day)
FY2024Q4 (2025-03-20,):
EPS: (Actual) vs. (Estimate) (%)
Revenue: 0.00 (Actual) vs. 150.00K (Estimate) (%)
Price Reaction: -2.29%(1-Day), -8.31%(5-Day)
Earnings Reaction
The chart below shows how VSTM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VSTM sees a -7.39% change in stock price 10 days leading up to the earnings, and a +6.26% change 10 days following the report. On the earnings day itself, the stock moves by -1.57%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 3.16% on the day following the earnings release and then changed by 17.19% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Verastem Inc (VSTM) Q3 2025 Earnings Call Summary
Positive
2025-11-04
The earnings call reflects positive sentiment due to early adoption of the new product, a strong financial runway, and strategic plans for clinical trials and market expansion. Despite some uncertainties in patient data and NCCN feedback, the overall outlook is optimistic with potential for label expansion and interest from partners. The positive adoption and feedback from healthcare providers, combined with a solid cash position, suggest a favorable stock price reaction.
Verastem Inc (VSTM) Q2 2025 Earnings Call Summary
Positive
2025-08-08
The earnings call summary indicates strong financial performance, positive product development updates, and effective market strategy, with minimal payer pushback and successful reimbursement strategies. The Q&A section reinforced positive sentiment with management's confidence in launch momentum and successful engagement with the healthcare community. Despite some uncertainties in EU approval timelines, the overall outlook is optimistic, with a focus on expansion and minimal financial concerns.
People Also Watch
FAQ
What were the key highlights of VSTM’s latest earnings report for FY2025Q3?
How did VSTM’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for VSTM for 2025/Q4?
How does VSTM’s stock price correlate with earnings forecast revisions?
What should investors expect from VSTM’s next earnings report?